OSAKA-BUSINESS-DEV-AGCY
15.12.2022 06:01:35 CET | Business Wire | Press release
The Osaka Business Development Agency, in cooperation with the Keihanshin Startup Ecosystem Consortium and JETRO Osaka, has jointly launched the brand, “Kansai Startup Mashups” to support startups from the Kansai region that are taking on global challenges. From this release and on, we will use "Kansai Startup Mashups" as a branding tool to promote various initiatives for startups in the Kansai region to the global market.
The first event will be held on January 25, 2023, and the call for participants begins today.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221214005391/en/
Kansai Startup Mashups in Kobe, 25 / Jan / 2023. (Graphic: Business Wire)
Osaka, Kyoto, and Kobe offer an environment conducive to startups, with a concentration of bio- and healthcare-related companies, Monozukuri (manufacturing), ICT-related companies, as well as universities and research institutes.
Due to its strength environment, the "Osaka-Kyoto-Kobe(Hyogo) Consortium" was selected in 2020 as a global hub city in the Japanese government's strategy to become a world-class start-up hub, and universities, companies, and local governments are working to form an ecosystem of collaboration.
And now, with the aim to further accelerate these efforts, Osaka, Kyoto, and Kobe have jointly launched "Kansai Startup Mashups" as a unified brand for support.
The newly launched "Kansai Startup Mashups" aims to create a world-class startup ecosystem in anticipation of the 2025 Kansai Expo and the post-Kansai Expo, and to create a framework that will lead to the birth of unicorn companies from the Kansai region and the creation and support of startups that will grow to become major players.
In this initiative, the three capitals of Osaka, Kyoto, and Kobe will collaborate to link the circle of cooperation and support among universities, businesses, and government, and to disseminate Kansai startups both domestically and internationally, creating new synergies through the exchange of cutting-edge technology and domestic and international wisdom.
As part of this effort, toward the end of the fiscal year, we will be holding three events under a unified brand; ANCHOR KOBE on Wednesday, January 25, 2023 and engawa KYOTO on February 7, 2023.
On March 2, 2023, a large-scale event will be held at QUINTBRIDGE (Osaka) to unify and communicate the potential of Kyoto, Osaka, and Kobe to become the world's first to realize a future society on the occasion of the Osaka-Kansai Expo.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005391/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Riskified Study Finds Consumers Aren’t Ready to Hand Over Control as AI Transforms Shopping, with Over Half Afraid of Online Fraud27.4.2026 14:00:00 CEST | Press release
New Q1 2026 “Agentic Commerce Pulse” survey from Riskified reveals a growing trust gap in agent-driven commerce, as consumers embrace AI across the shopping journey but remain hesitant to hand over control amid concerns over fraud, security, and accountability Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released the Q1 2026 edition of its Agentic Commerce Pulse, a quarterly research series tracking agentic commerce risks and consumer engagement. Following Riskified’s inaugural Q4 2025 survey, which first highlighted the rapid emergence of agent-driven commerce, the latest findings reveal a more complex reality: while AI adoption remains strong, consumer trust is not keeping pace. A widening gap is emerging between how shoppers use AI and how much control they are willing to give it. The survey, conducted among consumers across the United States and the United Kingdom, shows that AI is now firmly embedded in product discovery and decision-maki
Nine in 10 Expect Cross-Border M&A Surge, But 71% of Dealmakers Have Already Changed Course on Deals27.4.2026 14:00:00 CEST | Press release
90% of dealmakers expect cross-border M&A activity to increase over the next 12–24 months75% cite foreign direct investment screening as the biggest threat to deal completion88% report longer signing-to-close timelines than three years ago Cross-border M&A is set for a strong resurgence, with nine in 10 senior dealmakers expecting activity to increase over the next 12 to 24 months, according to new research from CSC, the leading provider of business administration and compliance solutions. However, despite this renewed momentum, execution risk is rising, with regulatory scrutiny and operational challenges making it harder to get deals over the line. CSC¹ surveyed 200 director level and above global dealmakers across private equity, corporate, legal, and advisory roles who have worked on cross-border transactions in the past two years. The report, The New Reality of Cross-Border M&A: More Deals, More Friction, explores how firms are navigating an increasingly complex global deal environ
Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients27.4.2026 13:43:00 CEST | Press release
For Trade and Medical Media Only The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal-free survival at Day 90 Study showed favourable benefit for toxicity-related discontinuations and drug-drug interactions (DDIs) Rezafungin was well tolerated, with a safety profile comparable to standard antimicrobial regimens (SARs) Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). The ReSPECT Phase III trial, one of the largest antifungal, multicentre, randomised, double-blind studies evaluated the efficacy and safety of once weekly rezafungin compared with a SAR for the prophylaxis of IFDs, including infections caused by Candida, Aspergillus, and Pneumocystis, in adults undergoing allogeneic HSCT. Patients undergoing a
vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 13:00:00 CEST | Press release
Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415938477/en/ Photo credit: Jos Schmid, Photographer
tesa Selects Kinaxis as the Digital Backbone for Global Integrated Business Planning Transformation27.4.2026 13:00:00 CEST | Press release
Kinaxis Maestro™ platform to serve as the foundation for a multi‑year transformation to resilient, globally orchestrated planning ecosystem Kinaxis® (TSX: KXS), a global leader in end‑to‑end supply chain orchestration, today announced that tesa SE, a global manufacturer of adhesive tapes and self-adhesive product solutions, has selected the Kinaxis Maestro™ platform as a core enabler of its global, multi‑year supply chain and integrated business planning (IBP) transformation. Following an extensive evaluation, tesa selected Kinaxis to support its evolution from regionally fragmented planning practices toward a centrally governed, globally orchestrated IBP operatingmodel. Kinaxis will support tesa in improving enterprise-wide transparency, strengthening resilience, and enabling faster, more informed decision making across an increasingly complex and volatile global supply chain network. With 130 years of innovation, tesa is one of the world’s leading manufacturers of adhesive tapes and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom